000			01500na a2200229 4500
003			H12O
005			20180417112020.0
008			130622s2012 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
245	0	0	_aFirst-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. _h[artículo]
260			_bOncology, _c2012
300			_a82(4):218-27.
500			_aFormato Vancouver: Thomssen C, Pierga JY, Pritchard KI, Biganzoli L, Cortés-Funes H, Petráková K, et al. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology. 2012;82(4):218-27.
501			_aPMID:22508241
504			_aContiene 32 referencias
520			_aThe prognosis for patients with triple-negative breast cancer (TNBC) is poor and treatment options are limited. Bevacizumab improves the efficacy of standard first-line therapy in locally recurrent/metastatic breast cancer (LR/mBC). The benefit of bevacizumab seen in patients with TNBC appears similar to that observed in the overall population. We conducted an exploratory analysis of patients with TNBC treated in the single-arm routine oncology practice ATHENA study.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1996.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c1996 _d1996